Fact-checked by Grok 2 weeks ago

CXCL1

CXCL1, also known as growth-regulated oncogene alpha (GRO-α) or melanoma growth stimulatory activity (MGSA), is a small cytokine belonging to the CXC chemokine family that functions primarily as a chemoattractant for neutrophils, playing a crucial role in acute inflammatory responses.^[1]^[2] Encoded by the CXCL1 gene located on human chromosome 4q13.3, it is secreted by various cell types including monocytes, macrophages, and epithelial cells in response to inflammatory stimuli such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α).^[2]^[3] The protein precursor consists of 107 amino acids, with the mature form being a 73-amino-acid polypeptide of approximately 8 kDa, featuring a characteristic CXC motif formed by two conserved cysteine residues separated by a single amino acid.^[1]^[3] CXCL1 exerts its effects by binding to the G-protein-coupled receptor CXCR2 on target cells, thereby mediating chemotaxis, angiogenesis, and the proliferation of certain cell types such as melanocytes and endothelial cells.^[1]^[3] In physiological contexts, CXCL1 regulates neutrophil trafficking from the bone marrow to sites of infection or injury, supports hematopoietic stem cell maintenance, and contributes to tissue repair processes including muscle regeneration and brain repair through effects on progenitor cells.^[3] Its expression is tightly controlled at transcriptional and post-transcriptional levels to balance immune activation and prevent excessive inflammation.^[4]

Discovery and Nomenclature

Historical Discovery

The discovery of CXCL1 began in the early 1980s with the identification of growth factor-inducible genes in murine cells. In 1983, researchers screened a cDNA library derived from platelet-derived growth factor (PDGF)-stimulated BALB/c-3T3 murine fibroblasts and isolated several immediate-early genes regulated by PDGF, including one termed KC, which was later recognized as the murine homolog of human CXCL1.^[5] This gene was characterized as rapidly induced by PDGF independently of DNA synthesis, suggesting its role as a competence factor in cell growth regulation. Subsequent work in 1989 confirmed KC as encoding a secreted protein related to platelet α-granule basic proteins, with homology to the human gro gene, highlighting its potential involvement in inflammation and growth signaling.^[6] In parallel, human counterparts were identified through studies on transformed cells. In 1988, the gro gene, later synonymous with CXCL1, was cloned from normal human foreskin fibroblasts and shown to be strongly induced by serum stimulation and phorbol 12-myristate 13-acetate (PMA), exhibiting early response kinetics similar to c-myc and c-fos, while interleukin-1 (IL-1) elicited even greater induction in growing cells.^[7] That same year, melanoma growth stimulatory activity (MGSA), an autocrine mitogen secreted by Hs294T human melanoma cells, was molecularly characterized via cDNA cloning and expression in mammalian cells, revealing it as the product of the groα gene and capable of stimulating melanoma cell proliferation.^[8] These findings positioned GRO-α (or MGSA) as a growth-regulated oncogene with mitogenic properties in both fibroblasts and tumor cells. The chemokine functions of CXCL1 were established in the late 1980s and early 1990s through functional assays. Key studies from 1987 to 1990 demonstrated its ability to act as a chemoattractant for neutrophils; for instance, in 1990, chemically synthesized MGSA was shown to induce human neutrophil chemotaxis, elastase release, and intracellular calcium mobilization in vitro, as well as neutrophil accumulation in vivo via intradermal injection in rats, albeit with lower potency than IL-8 for respiratory burst activation.^[9] Earlier related work in 1989 had linked GRO proteins to neutrophil activation, solidifying CXCL1's role beyond growth stimulation into inflammatory signaling. In 1996, the systematic nomenclature CXCL1 was proposed for this molecule as part of the chemokine classification system discussed at the Gordon Research Conference on Chemotactic Cytokines.^[10]

Nomenclature and Synonyms

CXCL1 was initially identified and described under several distinct names reflecting its early discovery contexts. It was first characterized as melanoma growth stimulatory activity (MGSA), an autostimulatory factor for melanoma cells, in studies from the late 1980s. Subsequently, the same protein was recognized as growth-regulated oncogene alpha (GRO-α) in transformed fibroblasts and as neutrophil-activating protein 3 (NAP-3) derived from platelets, highlighting its roles in cell growth and immune activation. In mice, the orthologous protein is known as keratinocyte-derived chemokine (KC), underscoring species-specific naming conventions in early research.^[11] The nomenclature of chemokines, including CXCL1, evolved from these ad hoc designations in the 1980s to a standardized system amid the rapid discovery of family members. Prior to unification, names like MGSA and GRO-α proliferated, complicating comparative studies across species and functions. In 1996, the Chemokine Nomenclature Subcommittee of the International Union of Immunological Societies/World Health Organization initiated efforts to systematize terminology, culminating in the adoption of a ligand-based classification by 2000.^[12] This shift replaced functional or source-based names with a structural framework, assigning CXCL1 as the systematic identifier within the CXC subfamily.^[12] Under the current IUPHAR/British Pharmacological Society (BPS) nomenclature, CXCL1 denotes C-X-C motif chemokine ligand 1, emphasizing the characteristic single amino acid (X) between the first two conserved cysteine residues in its structure.^[13] As a member of the CXC subfamily featuring the Glu-Leu-Arg (ELR) N-terminal motif, CXCL1 belongs to the broader chemokine superfamily, which comprises small chemotactic cytokines classified by cysteine spacing (C, CC, CXC, CX3C).^[13] Humans express 17 CXC chemokine ligands, with CXCL1 primarily signaling through the CXCR2 receptor to mediate its effects. This classification facilitates precise annotation in genomic databases and pharmacological research, superseding earlier synonyms while retaining them for historical reference.^[12]

Molecular Structure and Genetics

Protein Structure

The CXCL1 protein is synthesized as a precursor consisting of 107 amino acids, which undergoes processing to yield the mature form of 73 amino acids following cleavage of an N-terminal signal peptide of 34 residues.^[14] This maturation occurs in the secretory pathway, enabling the protein's release into the extracellular space. The gene encoding CXCL1 is located on chromosome 4.^[15] A defining feature of the mature CXCL1 is the ELR triad (Glu-Leu-Arg) positioned immediately N-terminal to the conserved CXC motif, which is critical for its interaction with the receptor CXCR2 and its chemotactic activity toward neutrophils.^[15] The three-dimensional structure of CXCL1 adopts the canonical chemokine fold, characterized by an N-terminal unstructured region, a three-stranded antiparallel β-sheet, a C-terminal α-helix, and two disulfide bonds stabilizing the core: one linking Cys9 to Cys34 and the other connecting Cys11 to Cys36 (numbered from the mature N-terminus).^[16] These bonds, formed between the first and third cysteines and the second and fourth cysteines of the CXC motif, respectively, maintain structural integrity. CXCL1 exists in both monomeric and dimeric forms, with dimerization occurring via hydrophobic interactions at the N-loop and β1-strand interfaces, influencing its localization and activity.^[17] CXCL1 features sites for interaction with glycosaminoglycans (GAGs), primarily through clusters of basic residues such as arginines and lysines on the protein surface, facilitating immobilization on extracellular matrix components like heparan sulfate.^[16] The protein binds its primary receptor, CXCR2, with high affinity, exhibiting a dissociation constant (Kd) in the range of 1-10 nM, which supports efficient signaling.^[18] Due to structural homology with CXCL8 (IL-8), particularly in the ELR motif and core fold, recent insights from the 2023 cryo-EM structure of the CXCR1-CXCL8-G protein complex (at 3.4 Å resolution) provide an analogous model for CXCL1-CXCR2 engagement, revealing how the chemokine's N-loop and β-strands insert into the receptor's extracellular pockets to induce activation.^[19]

Gene Location and Regulation

The CXCL1 gene is located on the long arm of human chromosome 4 at the q13.3 cytogenetic band, spanning approximately 1.8 kilobases with four exons and three introns.^[2]^[4] The gene encodes a 107-amino acid precursor protein that undergoes processing to yield the mature chemokine.^[2] The promoter region of CXCL1 contains binding sites for key transcription factors, including NF-κB, AP-1, and C/EBP, which respond to inflammatory stimuli to drive gene expression.^[20]^[4] Transcriptional activation is primarily upregulated by pro-inflammatory cytokines such as IL-1β and TNF-α, as well as lipopolysaccharide (LPS), through activation of the MAPK and NF-κB signaling pathways.^[4] Conversely, glucocorticoids suppress CXCL1 transcription, providing a mechanism for anti-inflammatory control.^[21] Post-transcriptional regulation of CXCL1 involves mRNA stability controlled by AU-rich elements (AREs) in the 3' untranslated region (3'UTR), which interact with RNA-binding proteins such as HuR (stabilizing) and TTP (destabilizing).^[22]^[23] These elements contribute to a basal mRNA half-life of approximately 30-45 minutes, which can be extended by inflammatory signals to fine-tune protein production.^[24] Epigenetic mechanisms further regulate CXCL1 expression, particularly through stimulus-induced histone acetylation at the promoter, which enhances chromatin accessibility and transcriptional activity.^[25] The CXCL1 gene is highly conserved across mammals, with orthologs such as the murine Cxcl1 (also known as KC) sharing significant sequence and functional similarity.^[26]

Expression Patterns

Cellular Sources

CXCL1 is principally produced by macrophages, neutrophils, and epithelial cells, serving as key cellular sources during inflammatory responses. Macrophages, particularly activated ones, represent a major source, releasing CXCL1 to orchestrate neutrophil recruitment. Neutrophils themselves contribute through autocrine production, amplifying their own mobilization at sites of infection or injury. Epithelial cells, such as those in the airways and intestines, also constitutively or inducibly express CXCL1 in response to microbial stimuli or cytokines like IL-1β and TNF-α.^[27]^[28]^[29] Additional cellular sources include fibroblasts, endothelial cells, and keratinocytes, which upregulate CXCL1 production primarily under stimulated conditions such as tissue injury or exposure to pro-inflammatory signals. For instance, endothelial cells secrete CXCL1 following activation by inflammatory mediators, contributing to local chemokine gradients. Monocytes transitioning to macrophages during differentiation exhibit enhanced CXCL1 output, heightening inflammatory amplification. In pathological contexts like tumors, cancer cells emerge as notable producers, fostering an immunosuppressive microenvironment via CXCL1. Expression from these sources is often regulated by transcription factors such as NF-κB in response to stimuli like LPS or cytokines.^[30]^[31]^[16] Activated macrophages can secrete substantial amounts of CXCL1, reaching concentrations of 10–100 ng/mL in vitro under stimulation, underscoring their potent role in chemokine-mediated immunity. Production patterns are largely conserved between humans and mice, though murine Cxcl1 (also known as KC) shows a more pronounced focus on neutrophil chemotaxis compared to the broader ligand repertoire in humans.^[32]^[28]

Tissue Distribution and Induction

CXCL1 exhibits low basal expression levels in various healthy human tissues, including the lung, skin, and gastrointestinal tract, where it is primarily detectable at minimal RNA and protein levels in epithelial and glandular cells. In contrast, expression is largely absent or undetectable in the brain and heart under normal conditions. These patterns are derived from comprehensive tissue profiling, highlighting CXCL1's role as an inducible rather than constitutively expressed chemokine.^[33]^[28] Upon inflammatory or injury stimuli, CXCL1 expression is markedly upregulated in specific tissues. In the lung, levels surge during pneumonia and other acute inflammatory responses, promoting neutrophil recruitment to the site of infection. Similarly, wound healing in skin tissue involves elevated CXCL1 production to facilitate immune cell infiltration and repair processes. In the liver, injury models such as ischemia-reperfusion or toxin-induced damage lead to substantial increases in CXCL1, correlating with heightened inflammation and neutrophil activation. Additionally, adipose tissue shows upregulated CXCL1 during obesity, contributing to chronic low-grade inflammation in metabolic disorders.^[34]^[35]^[36]^[37] Key inducers of CXCL1 expression include pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), which activate transcription via NF-κB and other pathways in epithelial and endothelial cells. Bacterial lipopolysaccharide (LPS) stimulates production through Toll-like receptor 4 (TLR4) signaling, as observed in macrophage and lung epithelial responses. Growth factors like platelet-derived growth factor (PDGF) also induce CXCL1 in fibroblasts and other stromal cells, supporting its role in tissue remodeling. In tumor microenvironments, hypoxia drives CXCL1 expression via hypoxia-inducible factor-1α (HIF-1α), enhancing angiogenic signaling.^[28]^[38]^[39]^[40]^[41] Recent studies as of 2024 emphasize adipose-derived CXCL1's involvement in metabolic inflammation, where it exacerbates insulin resistance and macrophage infiltration in obese visceral fat depots.^[42]

Physiological Functions

Chemotaxis and Immune Cell Recruitment

CXCL1 serves as a primary chemoattractant for neutrophils, directing their migration to sites of infection or injury through binding to the G protein-coupled receptor CXCR2 on the cell surface.^[43] This interaction enables neutrophils to sense and respond to CXCL1 gradients via G-protein-mediated signaling, which polarizes the cell and promotes directed movement.^[44] The ELR motif in the N-terminal region of CXCL1 is essential for high-affinity binding to CXCR2, facilitating this receptor-specific recruitment.^[45] Upon CXCR2 activation, CXCL1 triggers intracellular signaling cascades, including the PI3K/Akt and MAPK/ERK pathways, which drive actin cytoskeleton reorganization and polymerization necessary for cell motility.^[46] These pathways enhance pseudopod formation and uropod retraction, enabling neutrophils to migrate at speeds of approximately 10-20 μm/min in response to CXCL1 gradients.^[47] CXCL1 primarily induces chemotaxis, the directed migration along a gradient, though it can also exhibit chemokinetic effects by increasing random motility at higher concentrations.^[48] Its effects on monocytes are minor, as these cells express lower levels of CXCR2 and respond more robustly to other chemokines.^[49] In homeostatic conditions, CXCL1 plays a role in guiding neutrophil trafficking, including their release from the bone marrow into circulation to maintain steady-state levels.^[46] The potency of CXCL1 in inducing neutrophil chemotaxis is reflected in its EC50 value of approximately 1-10 nM, allowing effective recruitment even at low physiological concentrations.^[50]

Angiogenesis and Wound Healing

CXCL1 exerts pro-angiogenic effects by binding to the CXCR2 receptor on endothelial cells, thereby inducing their proliferation, migration, and formation of capillary-like structures. This process involves activation of intracellular signaling pathways such as ERK1/2 and EGF, with CXCL1 acting in an autocrine manner as it is expressed and secreted by endothelial cells themselves. Studies demonstrate that interference with CXCL1, such as through neutralizing antibodies or silencing, significantly reduces endothelial cell viability, migration, and angiogenic potential in vitro and in vivo models.^[51] In addition to direct effects on endothelial cells, CXCL1 enhances angiogenesis through synergy with vascular endothelial growth factor A (VEGF-A). CXCL1 upregulates VEGF-A expression in endothelial cells via CXCR2 signaling, promoting tube formation and overall vascularization, as observed in decidual tissue during early pregnancy where CXCL1 neutralization impairs angiogenesis that is reversible by exogenous VEGF-A. This interplay underscores CXCL1's role in physiological vascular development, including homeostatic processes like decidualization.^[52] In wound healing, CXCL1 contributes to the formation of granulation tissue by driving angiogenesis and facilitating tissue remodeling at injury sites. It supports the transition from inflammation to repair by promoting endothelial cell responses essential for new vessel ingrowth into the wound bed. CXCR2-deficient mice, which lack responsiveness to CXCL1 as a primary ligand, exhibit delayed wound closure, reduced granulation tissue cellularity, and impaired epithelial resurfacing, highlighting the chemokine's necessity in timely repair.^[53] Recent investigations have extended these findings to specific contexts, such as peritoneal membrane vascularization in dialysis patients, where mesothelium-derived CXCL1, stimulated by IL-17, correlates with increased microvessel density and drives endothelial tube formation in vitro.^[54]

Hematopoietic and Tissue Repair Roles

CXCL1 supports the maintenance of hematopoietic stem cells (HSCs) in the bone marrow niche, where it promotes HSC retention and quiescence through CXCR2 signaling on HSCs and stromal cells.^[3] In tissue repair, CXCL1 contributes to muscle regeneration by recruiting neutrophils that aid in clearing debris and modulating macrophage polarization to support myoblast proliferation and differentiation. In brain development, CXCL1 influences neural progenitor cell migration and differentiation via CXCR2, playing a role in cortical layering and gliogenesis.^[3]

Pathological Roles

In Cancer

CXCL1 contributes to cancer progression through multiple mechanisms, primarily by binding to its receptor CXCR2 in an autocrine manner to enhance tumor cell proliferation and invasion. This signaling axis activates downstream pathways such as ERK1/2 and PI3K/AKT, promoting cell survival and motility in various malignancies. Additionally, tumor-derived CXCL1 recruits myeloid-derived suppressor cells (MDSCs) and neutrophils into the tumor microenvironment, where these cells exert immunosuppressive effects by inhibiting CD8+ T cell activity and fostering an environment conducive to tumor evasion of immune surveillance.^[55]^[56]^[35] In angiogenesis, CXCL1 upregulates vascular endothelial growth factor (VEGF) expression, leading to increased microvessel density and enhanced nutrient supply to tumors. Studies in colorectal and lung cancers have shown that elevated CXCL1 levels correlate with higher VEGF production and tumor vascularization, thereby supporting metastatic spread. In breast cancer, stromal CXCL1 expression is particularly notable, as it predicts disease recurrence and reduced overall survival, with high levels associated with advanced tumor grades.^[57]^[35]^[58] Specific roles of CXCL1 have been identified in several cancers. In colorectal cancer, CXCL1 promotes immune escape by inducing autophagy-mediated degradation of major histocompatibility complex class I (MHC-I) molecules on tumor cells, thereby reducing antigen presentation to cytotoxic T cells, as demonstrated in a 2023 study. In lung cancer, CXCL1 sustains cancer stem cell features through TGFβ1 induction, contributing to self-renewal and therapy resistance. Similarly, in pancreatic cancer, cell-autonomous CXCL1 expression maintains tolerogenic circuits and stromal inflammation via neutrophil recruitment, exacerbating tumor progression.^[59]^[60]^[61] Recent research highlights the CXCL1-CXCR2 axis in therapy resistance, particularly chemotherapy, through paracrine loops that protect tumor cells from apoptosis. A 2024 study in breast cancer revealed that extracellular vesicle-released CXCL1 from dying cells during chemotherapy fosters resistance by activating stromal signaling. Elevated serum and tissue CXCL1 levels serve as prognostic indicators, linking to poor survival across cancers like colorectal and gastric, positioning it as a potential biomarker for monitoring disease aggressiveness.^[62]^[55]^[63]

In Inflammatory Diseases

CXCL1 plays a significant role in driving neutrophil-mediated inflammation in various non-cancerous inflammatory conditions, particularly by promoting excessive immune cell recruitment that exacerbates tissue damage. In inflammatory bowel disease (IBD), such as Crohn's disease, CXCL1 is overexpressed in affected patients, contributing to mucosal inflammation and injury through enhanced neutrophil infiltration. ^[64] Elevated serum levels of CXCL1 correlate with disease activity in Crohn's disease, serving as a potential biomarker for monitoring progression. ^[65] Similarly, in the synovium of rheumatoid arthritis (RA) patients, CXCL1 facilitates neutrophil chemotaxis, amplifying joint inflammation and correlating with synovial fibroblast activation that promotes pro-inflammatory mediator production, such as cyclooxygenase-2 (COX-2). ^[66] ^[67] ^[68] In acute liver injury, including acetaminophen (APAP)-induced models, CXCL1 exacerbates hepatotoxicity by recruiting neutrophils, leading to increased infiltration and subsequent hepatocyte damage. ^[69] Neutralization of CXCL1 in these models reduces neutrophil influx and attenuates liver injury, highlighting its pathological contribution. ^[70] Mechanistically, CXCL1 signals through its receptor CXCR2 to amplify inflammatory cascades, including cytokine storms, by sustaining neutrophil activation and release of additional pro-inflammatory factors in conditions like sepsis and chronic inflammation. ^[71] ^[72] Despite its pro-inflammatory effects, CXCL1 exhibits protective roles in certain infections by facilitating timely neutrophil recruitment for pathogen clearance and aiding inflammatory resolution. ^[73] For instance, in bacterial and fungal infections, CXCL1-mediated neutrophil activation is essential for host defense and limiting tissue damage during the resolution phase. ^[74] ^[75] Recent studies (2023–2024) have linked sustained CXCL1 expression to liver fibrosis progression via prolonged neutrophil activation and extracellular trap formation, which perpetuate hepatic inflammation and scarring. ^[34] ^[76] In acute-on-chronic liver failure models, CXCL1 knockdown reduces neutrophil infiltration and inflammatory cytokine expression, mitigating fibrosis. ^[34] Therapeutically, CXCR2 inhibitors have shown promise in preclinical models of inflammatory diseases by blocking CXCL1 signaling, thereby reducing neutrophil recruitment and inflammation. In RA models, CXCR2 antagonism decreases joint swelling and disease scores. ^[77] Similarly, these inhibitors attenuate lung and liver inflammation in relevant injury models, suggesting potential for clinical translation in neutrophil-driven conditions. ^[78] ^[79]

In Neurological Disorders

CXCL1 contributes to pain sensitization in both peripheral and central nervous systems by signaling through its primary receptor CXCR2, which is expressed on nociceptors and microglia.^[80] This pathway promotes nociceptor activation and central sensitization, leading to heightened pain responses in inflammatory conditions. In models of persistent inflammatory pain, such as those induced by complete Freund's adjuvant (CFA), CXCL1 upregulation in spinal cord astrocytes drives the expression of pronociceptive genes, exacerbating mechanical and thermal hypersensitivity.^[81] Spinal administration of CXCL1 similarly induces rapid neuronal activation and pain hypersensitivity via CXCR2 on dorsal horn neurons.^[82] During neural development, CXCL1 plays a regulatory role by inhibiting the migration of oligodendrocyte precursor cells (OPCs) in the spinal cord through CXCR2 signaling. This inhibition arrests OPC movement in response to platelet-derived growth factor (PDGF) stimulation, thereby controlling their positioning and contributing to proper myelination patterns in the developing central nervous system. Disruption of this CXCL1-CXCR2 interaction impairs OPC distribution, highlighting its importance in spinal cord organization.^[83] In neurological disorders, CXCL1 is implicated in inflammatory responses following peripheral nerve injury. After sciatic nerve transection, the CXCL1-CXCR2 axis promotes macrophage recruitment and activation at the injury site, amplifying local inflammation and potentially hindering regeneration.^[84] In hypoxic-ischemic brain injury in neonatal models, CXCL1 expression is upregulated in brain tissue, driving microglia activation and contributing to exacerbated neuronal damage when preceded by inflammation, as demonstrated in a 2020 study on inflammation-sensitized injury.^[85] Similarly, in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis, induced CNS expression of CXCL1 enhances disease severity by facilitating neutrophil infiltration into the central nervous system, promoting demyelination and neurologic deficits.^[86] Mechanistically, astrocytic release of CXCL1 is mediated by NF-κB activation in response to inflammatory stimuli, enabling crosstalk with neuronal CXCR2 to sustain pain and neuroinflammation in regions like the periaqueductal gray.^[87] A 2023 review underscores the CXCL1-CXCR2 axis's role in activating intracellular pathways within neurons, leading to neuronal damage across various neurological conditions.^[88]

In Cardiovascular and Musculoskeletal Diseases

CXCL1 contributes to the pathogenesis of cardiac fibrosis by activating cardiac fibroblasts and promoting the secretion of extracellular matrix components such as collagen I and collagen III. In models of heart failure and atrial fibrillation, elevated CXCL1 levels enhance fibroblast proliferation and induce endoplasmic reticulum stress through upregulation of TXNDC5, leading to fibrotic remodeling that exacerbates myocardial stiffness and dysfunction.^[27]^[89] In atherosclerosis, CXCL1 exhibits a dual role: it drives early inflammatory responses by recruiting neutrophils and monocytes to endothelial sites of dysfunction, thereby promoting lesion formation, while in later stages, it supports plaque stabilization through mechanisms that limit further immune cell infiltration and vascular remodeling.^[90]^[91] In musculoskeletal disorders, CXCL1 influences bone remodeling by serving as a target gene of parathyroid hormone in osteoblasts, where it attracts osteoclast precursors and modulates osteogenesis in mesenchymal stem cells.^[92]^[93] Elevated CXCL1 concentrations have been detected in the synovial fluid of patients with osteoarthritis, where it stimulates interleukin-6 production in synovial fibroblasts via the CXCR2-c-Raf-MAPK-AP-1 pathway, amplifying local inflammation and cartilage degradation.^[94] In muscle tissue, CXCL1 expression is upregulated following injury, such as in freeze-induced trauma models, where it recruits neutrophils and contributes to the initial inflammatory phase that facilitates repair but can prolong damage if dysregulated. Regarding metabolic aspects of muscle function, muscle-derived CXCL1 overexpression attenuates diet-induced obesity in murine models by enhancing fatty acid oxidation capacity in skeletal muscle, reducing fat accumulation without altering food intake or energy expenditure.^[95] This protective effect is mediated through improved mitochondrial function and is supported by subsequent analyses confirming CXCL1's role in metabolic homeostasis during high-fat feeding.^[96] In ischemic conditions, such as myocardial ischemia-reperfusion injury, CXCL1 recruits neutrophils to the infarcted area, where their activation contributes to tissue damage via release of reactive oxygen species and proteases, worsening post-ischemic remodeling.^[27]^[97]

References

[1]
CXCL1 - Growth-regulated alpha protein - Homo sapiens (Human)
Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion.
[2]
2919 - Gene ResultCXCL1 C-X-C motif chemokine ligand 1 [ (human)]
Aug 19, 2025 · CXCL1 promotes immune escape in colorectal cancer by autophagy-mediated MHC-I degradation. Biological function of C-X-C Motif Chemokine Ligand 1 ...
[3]
The Importance of CXCL1 in Physiology and Noncancerous ...
This review describes the role of CXCL1, a chemokine crucial in inflammation as a chemoattractant for neutrophils, in physiology and in selected major ...
[4]
CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability ...
The CXCL1 gene is localized in the 4q12–q13 CXC chemokine gene cluster [12,15]. This region includes the closely located loci of other CXC sub-family chemokines ...
[5]
Molecular cloning of gene sequences regulated by platelet-derived ...
We have screened a cDNA library for gene sequences that are regulated by platelet-derived growth factor (PDGF) in BALB/c-3T3 cells.Missing: initial | Show results with:initial
[6]
https://www.jbc.org/article/S0021-9258(19)84972-4/fulltext
[7]
Functional diversity of gro gene expression in human fibroblasts and ...
Previous studies of gro and related genes that are overexpressed in transformed fibroblasts suggest that gro may encode a specific growth regulator.
[8]
Molecular characterization and chromosomal mapping of melanoma ...
Melanoma growth stimulatory activity (MGSA) is a mitogenic polypeptide secreted by Hs294T human melanoma cells. Comparison of the N-terminal sequences of ...
[9]
Neutrophil-activating properties of the melanoma growth-stimulatory ...
May 1, 1990 · To test this hypothesis, MGSA was chemically synthesized and tested for its effects on human neutrophils. It was found to induce chemotaxis, ...
[10]
HUMAN CHEMOKINES: An Update - Annual Reviews
The new, simplified nomenclature for chemokine receptors, which was elaborated at the 1996 Gordon Research Conference on. “Chemotactic Cytokines” (Table 1) ...
[11]
Chemokine Nomenclature - R&D Systems
Chemokine Nomenclature Contents: C Family, CX3C Family, CC Family, CXC Family. NOTE: Alternate names shown in BOLD represent the most commonly recognized name.Missing: 1996 | Show results with:1996
[12]
CXCL1 | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY
CXCL1 is a CXC motif chemokine expressed by macrophages, neutrophils and epithelial cells, that acts via the chemokine receptor CXCR2.
[13]
[PDF] Human CXCL1/GROα Immunoassay - R&D Systems
The GROα cDNA encodes a 107 aa precursor protein from which the N-terminal 34 aa residues are cleaved to generate the 73 aa residue mature GROα. There are ...
[14]
155730 - CHEMOKINE, CXC MOTIF, LIGAND 1; CXCL1 - OMIM
... glu-leu-arg sequence adjacent and N terminal to the CXC motif. ELR types are chemotactic for neutrophils, while non-ELR types are chemotactic for ...
[15]
CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability ...
CXCL1 is one of the most important chemokines, part of a group of chemotactic cytokines involved in the development of many inflammatory diseases.Missing: BALB/ 3T3
[16]
Structural basis of CXC chemokine receptor 1 ligand binding and ...
Jul 11, 2023 · Both receptors form two disulphide bonds on their external surfaces. One is formed by a cysteine just downstream of the N-terminal tail, linking ...Results · Structures Of Cxcr1 · Activation Of Cxcr1<|control11|><|separator|>
[17]
Fine Tuning the Transcriptional Regulation of the CXCL1 Chemokine
The constitutive expression of chemokines such as CXCL1 has been correlated with growth, angiogenesis, and metastasis of cancers such as melanoma.
[18]
Cell‐Specific Regulation of Inflammatory Cytokines and Acute ...
Nov 28, 2023 · In PHH from donor 2, DEX treatment inhibited protein expression and secretion of CXCL1 and CXCL8 induced by TNFα and/or LPS, whereas CXCL2 ...
[19]
HuR is required for IL-17-induced Act1-mediated CXCL1 and ... - NIH
Many cytokine and chemokine mRNAs exhibit very short half-lives due to the presence of AU-rich sequence elements (ARE) located within their 3' untranslated ...
[20]
The role of post-transcriptional regulation in chemokine gene ...
The occurrence of a third signal mediated by the p38 MAPK, induced by strong inflammatory stimuli such as IL-1, TNF-α and LPS, mediates CXCL8 mRNA stabilisation ...
[21]
Interleukin-17 regulates CXCL1 mRNA stability via an AUUUA ...
The mRNA exhibits a half-life of approximately 30 to 45 minutes that can be prolonged 2–4 fold following stimulation through multiple Toll Interleukin 1 ...
[22]
Opioids Enhance CXCL1 Expression and Function After Incision in ...
Jun 2, 2014 · Moreover, both CXCL1 and CXCR2 have been demonstrated to be epigenetically regulated via histone acetylation. Epigenetic regulation ...
[23]
https://publications.ersnet.org/content/erj/26/5/933
[24]
A Review of CXCL1 in Cardiac Fibrosis - Frontiers
Chemokine C-X-C motif ligand-1 (CXCL1), principally expressed in neutrophils, macrophages and epithelial cells, is a valid pro-inflammatory factor which ...
[25]
The Potential Importance of CXCL1 in the Physiological State and in ...
Dec 22, 2022 · In atherosclerotic plaque, endothelial cells, macrophages and activated mast cells are responsible for CXCL1 production. This chemokine causes ...
[26]
The Potential Importance of CXCL1 in the Physiological ... - MDPI
Dec 22, 2022 · Factors that increase CXCL1 expression are pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) [9,10].
[27]
CXCL1 Chemokine - an overview | ScienceDirect Topics
CXCL1 chemokines are defined as important neutrophil chemoattractants that play a role in innate immunity and pro-angiogenic activities. They are part of a ...
[28]
Expression of CXCL1 in human endothelial cells induces ... - Nature
Jun 3, 2013 · Specifically, CXCL1 is expressed and secreted from human endothelial cells. Interference of CXCL1 function using neutralizing antibodies ...
[29]
Induction of CXCL1 by Extracellular Matrix and Autocrine ...
Similarly, INS-1E cells treated with IL-1β and IFNγ produce chemokines such as IP10, CXCL1, and CXCL2 (17). In both type 1 and type 2 diabetes, cytokines seem ...Induction Of Cxcl1 By... · Cxcl1 Is Secreted By... · Nf-κb And Il-1 Are Key...
[30]
Tissue expression of CXCL1 - Summary - The Human Protein Atlas
The value ranges from 0 and 1, where 0 indicates identical expression across all cells/tissue types, while 1 indicates expression in a single cell/tissue type.
[31]
Knockdown of CXCL1 improves ACLF by reducing neutrophil ...
Sep 15, 2023 · We found that the knockdown of CXCL1 attenuated the infiltration of neutrophils in the mouse liver, reduced the expression of inflammatory ...
[32]
The role of CXCL family members in different diseases - Nature
Jul 1, 2023 · According to the existence of ELR motif (Glu-Leu-Arg) located at N ... Plasma levels of CXC motif chemokine 1 (CXCL1) and chemokine 8 ...
[33]
Serum CXCL1 Is a Prognostic Factor for Patients With Hepatitis B ...
Jul 27, 2021 · Overall, serum CXCL1 can serve as a biomarker indicating the severity of disease and prognosis for patients with HBV-ACLF.
[34]
Increased serum CXCL1 and CXCL5 are linked to obesity ...
Our data are consistent with other studies showing that high-fat diet can increase CXCL1 levels in adipose tissue (Oliveira et al. 2013) and that serum ...
[35]
TNF-α induces CXCL1 chemokine expression and release in human ...
Feb 3, 2014 · TNF-α stimulates CXCL1 release from human ECs through JNK-mediated CXCL1 mRNA expression and p38 MAPK- and PI-3K-mediated CXCL1 secretory processes.
[36]
A Systematic Analysis of the Peripheral and CNS Effects of Systemic ...
CNS expression of chemokines. The current data show a clear acute CNS induction of the chemokine transcripts CXCL1 and CCL2 after LPS, IL-1β and TNF-α, and both ...
[37]
Nanofibrous Scaffolds Incorporating PDGF-BB Microspheres Induce ...
In our study, PDGF induced chemokine gene expression in both dose-dependent and duration-dependent manners. The CXCL1 gene expression induced by 25 µg PDGF ...
[38]
The Effect of Hypoxia on the Expression of CXC Chemokines and ...
Jan 15, 2021 · This paper reviews all available information on hypoxia-induced changes in the expression of all CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL ...
[39]
Adipocyte-derived CXCL10 in obesity promotes the migration and ...
Dec 19, 2024 · The chemokines, including CXCL1, CXCL5, CXCL10, and CXCL11, are upregulated in the adipose tissue of obesity [3, 4], and the expression of ...
[40]
Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung - NIH
The chemokine CXCL1 and its receptor CXCR2 play a crucial role in host immune response by recruiting and activating neutrophils for microbial killing at the ...
[41]
How do chemokines navigate neutrophils to the target site
The next best-studied NAC CXCL1 essentially functions as a CXCR2 agonist. Studies from these two chemokines capture the complexity of the NAC-CXCR1/CXCR2 system ...
[42]
International Union of Pharmacology. LXXXIX. Update on the ...
ELR+ CXC chemokines are categorized as inflammatory because they recruit neutrophils from blood to sites of infection and inflammation, but they may also have a ...Missing: speed | Show results with:speed
[43]
Multiple Roles for Chemokines in Neutrophil Biology - Frontiers
Jul 8, 2020 · CXCR2 activates many G-protein–induced signaling cascades: PI3K/Akt inducing cell migration, PLC/PKC that affects cell function, and mitogen ...
[44]
Article Astrocyte- and Neuron-Derived CXCL1 Drives Neutrophil ...
Sep 15, 2020 · The CXCL1-CXCR2 axis represents an attractive therapeutic target to limit neutrophil-mediated morbidity in HSV-1 encephalitis.
[45]
The Chemokine System in Innate Immunity - PMC - PubMed Central
Chemokines are chemotactic cytokines that control cell migration and cell positioning throughout development, homeostasis, and inflammation. The immune system, ...
[46]
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory ...
CXCL2-CXCR2 axis helps in the recruitment of tumor-associated neutrophils and thus, regulated colitis-associated colon cancer in mice [287]. Breast Cancer ...
[47]
Drugging the Mighty Neutrophil in Chronic Obstructive Pulmonary ...
The mean EC50 for COPD neutrophil chemotaxis to CXCL1 was 4.8 nM, a concentration close to that achievable in the plasma of patients with COPD (9). Of interest, ...
[48]
Expression of CXCL1 in human endothelial cells induces ... - PubMed
In this report, we present data that expand on the role of CXCL1 in human endothelial cells inducing angiogenesis.
[49]
CXCL1 stimulates decidual angiogenesis via the VEGF-A pathway ...
Mar 26, 2021 · Angiogenesis is critical to establishing a successful pregnancy. The chemokine (C-X-C motif) ligand 1 (CXCL1) is a small cytokine belonging ...
[50]
Delayed wound healing in CXCR2 knockout mice - PubMed - NIH
Previous studies demonstrated that the CXC chemokine, MGSA/GRO-alpha and its receptor, CXCR2, are expressed during wound healing by keratinocytes and ...
[51]
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and ...
These results indicate that IL-8 activates both the CXCR1 and the CXCR2 on microvascular endothelial cells, using different signal transduction cascades.Missing: migration angiogenesis
[52]
Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 ...
Feb 4, 2022 · We have identified the crucial contribution of mesothelial cell-derived angiogenic CXC chemokine ligand 1 (CXCL1) to peritoneal angiogenesis in PD.Missing: wound healing
[53]
The CXCL1-CXCR2 Axis as a Component of Therapy Resistance, a ...
CXCL1 plays a critical role in cancer progression by directly affecting tumor cells. It promotes cancer cell proliferation [5,6,7] and supports the self-renewal ...
[54]
CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis ...
Our study provides the first evidence that primary malignant cell-secreted VEGFA stimulates tumor-associated macrophages to produce CXCL1.
[55]
CXCL1 Promotes Tumor Growth Through VEGF Pathway Activation ...
Apr 10, 2015 · These results suggested that CXCL1 increased local tumor growth through activation of VEGF signaling which may have mechanistic implications for ...Missing: wound healing
[56]
Elevated CXCL1 Expression in Breast Cancer Stroma Predicts Poor ...
Oct 24, 2014 · Results: Elevated CXCL1 expression in breast cancer stroma correlated with tumor grade, disease recurrence and decreased patient survival.
[57]
https://pubmed.ncbi.nlm.nih.gov/25641338/
[58]
TGFβ1 induces CXCL1 to promote stemness features in lung cancer
Dec 30, 2023 · We found that CXCL1 knockdown inhibited TGFβ1-promoted stemness gene expression, chemo drug resistance, and tumorigenicity.Missing: embryonic | Show results with:embryonic
[59]
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries ... - PubMed
Jun 2, 2023 · Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Cancer Discov.
[60]
Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells ...
Apr 23, 2024 · For M1 and M2 macrophage induction, cells were stimulated with 100 ng/ml LPS, or 10 ng/ml IL-4 and 10 ng/ml IL-13 for 24 h, respectively. The ...
[61]
CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated ...
CXCL1 is closely associated with tumor progression and poor survival. DACH1 significantly inhibits the expression of CXCL1 and indicates good prognosis.Missing: embryonic | Show results with:embryonic
[62]
Role of IL-1ra and Granzyme B as biomarkers in active Crohn's ...
Conclusions: We identified that IL1RA, CXCL1, and GZMB are overexpressed in CD patients. Serum IL1RA and GZMB levels were markedly increased in CD patients, ...
[63]
Serum Analyte Profiles Associated With Crohn's Disease ... - PubMed
Jan 5, 2022 · In particular, CXCL9, CXCL1, and interleukin IL-6 had the greatest effect and were highly significant (P < 5 × 10-7). We also identified 9 ...
[64]
Growth-related gene product alpha. A chemotactic cytokine for ...
Oct 1, 1995 · Leukocyte recruitment is critical in the inflammation seen in rheumatoid arthritis (RA). To determine whether the chemokine growth-related ...
[65]
CXCL1 enhances COX-II expression in rheumatoid arthritis synovial ...
We found that CXCL1 promoted cyclooxygenase-2 (COX-II) expression in a dose- and time-dependent manner in rheumatoid arthritis synovial fibroblasts (RASFs).
[66]
Mig, GRO alpha and RANTES messenger RNA expression in lining ...
To investigate lymphocyte and monocyte recruitment-specific chemokine expression in synovial tissues from patients with rheumatoid arthritis (RA), ...
[67]
Mesenchymal stromal cells alleviate APAP-induced liver injury via ...
Nov 3, 2024 · In addition, neutralization of CXCL1 reduced APAP-induced liver damage, which was accompanied by decreased neutrophil infiltration. Importantly, ...
[68]
Mesenchymal stromal cells alleviate APAP-induced liver injury via ...
Nov 3, 2024 · CXCL1 is involved in the exacerbation of liver injury during APAP-induced ALF. To further examine the impact of CXCL1 on APAP-induced liver ...
[69]
Rationale for CXCR2 antagonists for the treatment of COVID-19
Jul 17, 2020 · We summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option.
[70]
The immunological function of CXCR2 in the liver during sepsis
Nov 30, 2022 · The chemokine receptor CXCR2 and its ligands, especially CXCL8, are crucial mediators for the progression of liver inflammation and liver failure in sepsis.
[71]
Chemokine CXCL1 mediated neutrophil recruitment - Nature
Sep 14, 2016 · The trapped CXCL1 dimer was designed by mutating Asn-27 with cysteine, which results in a disulfide across the dimer interface. The ...
[72]
CXCL1 and CXCL2: Key Regulators of Host Defense Against ...
May 15, 2025 · The purpose of this study was to investigate the roles of chemokines CXCL1 and CXCL2 in the innate immune defense against P. verrucosa infections.Cxcl1 And Cxcl2: Key... · Deficiency Of Cxcl1 And... · Discussion
[73]
Chemokine CXCL1/KC and its Receptor CXCR2 Are Responsible ...
Both CXCL1 and CXCR2 play an important role in chemokine expression and neutrophil infiltration following adenoviral corneal infection.
[74]
When alcohol and fat meet, neutrophil traps form to promote liver injury
CXCL1 is a key chemokine to activate and recruit neutrophils, playing an important role in inducing liver injury induced by HFD feeding plus ethanol binges.
[75]
Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 ...
Jan 1, 2010 · Targeting neutrophil migration with the CXCR2/CXCR1 antagonist SCH563705 led to a dose-dependent decrease in clinical disease scores and paw ...
[76]
Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung ...
Key results: Pharmacological inhibition of CXCR2 by Reparixin reduced CXCL1-induced leukocyte arrest in the microcirculation of the cremaster muscle, but ...
[77]
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo ...
SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.
[78]
CXCL1 Promotes Fibrotic Remodeling in Atrial Fibrillation via ...
Oct 31, 2025 · In cardiac fibroblasts, CXCL1 promoted the secretion of Collagen I, Collagen III, and TGF‐ β 1. Notably, both ERS inhibition and TXNDC5 ...
[79]
The Role of CXC Chemokines in Cardiovascular Diseases - Frontiers
These studies have shown that CXCL1 promotes inflammation early in atherosclerosis but plays a protective role in late atherosclerosis by promoting plaque ...Missing: dual | Show results with:dual
[80]
Chemokines in Atherosclerosis | Arteriosclerosis, Thrombosis, and ...
Jan 16, 2014 · In addition, CXCL1 can recruit leukocytes to the vessel wall and has been implicated to mediate the progression of atherosclerosis in response ...<|separator|>
[81]
Chemokine Cxcl1 Is a Novel Target Gene of Parathyroid Hormone ...
The chemokine Cxcl1 is an immediate response gene of PTH/PTHrP in osteoblasts that can attract osteoclast precursors, suggesting a role in bone physiology.Missing: non- | Show results with:non-
[82]
Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and ...
We identified a novel role for Cxcl1 in regulating (i) bone-metastatic prostate cancer growth, (ii) MSC osteogenesis and cancer-induced osteogenesis, and (iii) ...
[83]
CXCL1 contributes to IL-6 expression in osteoarthritis and ... - NIH
Furthermore, this report found a higher expression level of CXCL1 in RA synovial fluid compared with OA synovial fluid. Our current work focuses on the ...
[84]
Muscle-derived expression of the chemokine CXCL1 attenuates diet ...
We show that overexpression of muscle CXCL1 attenuates diet-induced fat accumulation and that this effect is associated with increased ex vivo fatty acid ...
[85]
The Role of Chemokines in Obesity and Exercise-Induced Weight ...
In obese patients, especially those with type 2 diabetes mellitus, CXCL14 levels usually show a decrease in blood circulation and subcutaneous adipose tissue; ...
[86]
Role of Neutrophils in Cardiac Injury and Repair Following ... - MDPI
Neutrophils can promote myocardial injury by releasing reactive oxygen species, granular components, and pro-inflammatory mediators.